Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorKohmer, Niko-
Autor(es): dc.creatorWesthaus, Sandra-
Autor(es): dc.creatorRühl, Cornelia-
Autor(es): dc.creatorCiesek, Sandra-
Autor(es): dc.creatorRabenau, Holger F.-
Data de aceite: dc.date.accessioned2026-02-09T11:15:02Z-
Data de disponibilização: dc.date.available2026-02-09T11:15:02Z-
Data de envio: dc.date.issued2020-08-20-
Data de envio: dc.date.issued2020-08-20-
Data de envio: dc.date.issued2020-08-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/42512-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1386653220302225-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1136844-
Descrição: dc.descriptionSerological SARS-CoV-2 assays are urgently needed for diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how recently commercially available, high-throughput immunoassays, using different recombinant SARS-CoV-2 antigens, perform with clinical samples. Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect™ i2000 (N protein-based)), Roche cobas™ e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON®XL platform (S1 and S2 protein-based), VIRCLIA® automation system (S1 and N protein-based) in comparison to two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT). We tested follow up serum/plasma samples of individuals PCR-diagnosed with COVID-19. When calculating the overall sensitivity, in a time frame of 49 days after first PCR-positivity, the PRNT as gold standard, showed the highest sensitivity with 93.3% followed by the dual-target assay for the VIRCLIA® automation system with 89%. The overall sensitivity in the group of N protein-based assays ranged from 66.7 to 77.8% and in the S protein-based-assays from 71.1 to 75.6%. Five follow-up samples of three individuals were only detected in either an S and/or N protein-based assay, indicating an individual different immune response to SARS-CoV-2 and the influence of the used assay in the detection of IgG antibodies. This should be further analysed. The specificity of the examined assays was ≥ 97%. However, because of the low or unknown prevalence of SARS-CoV-2, the examined assays in this study are currently primarily eligible for epidemiological investigations, as they have limited information in individual testing.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceJournal of Clinical Virology-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectImmunoglobulin G (IgG)-
Palavras-chave: dc.subjectAssay-
Palavras-chave: dc.subjectEvaluation-
Palavras-chave: dc.subjectPlaque reduction neutralization test (PRNT)-
Título: dc.titleBrief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.